Jamie E. Medina; Akshaya V. Annapragada; Pien Lof; Sarah Short; Adrianna L. Bartolomucci; Dimitrios Mathios; Shashikant Koul; Noushin Niknafs; Michaël Noë ...

Deep learning (DL) delineation of the prostate gland and prostate cancer detection on PSMA PET/CT: results from prospective, randomised, multi-centre pro-PSMA trial ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

Bristol Myers Squibb (BMS) faces a $6.7 billion lawsuit alleging that the company purposely delayed approval of Celgene-developed drugs to avoid paying Celgene shareholders owning contingent value ...

1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. *Corresponding Author: Jaleh Fallah, U.S. Center for Drug Evaluation and Research, Office of New ...

1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 2Department of Medicine, Weill Cornell Medical College, New York, New York. *Corresponding Author: Claire F.

1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 9Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York ...

1Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China. 2China-US (Henan) Hormel Cancer Institute, Zhengzhou, China. 3Tianjian Laboratory of Advanced ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license ...

Major Finding: Antitumor T cells are recruited to intracranial metastases through ICAM-1 + peritumoral venous vessels (PVV). Concept: PVVs mediate T-cell recruitment and motility, which can be ...

Today, Merck announced that it will acquire LaNova Medicines’ PD-1/VEGF bispecific antibody, LM-299, for $588 million upfront plus financial awards that could reach $2.7 billion if certain development ...

Pancreatic cancer remains a formidable challenge due to high mortality rates and limited therapeutic options due to late detection of the cancer. Recent literature has focused on investigating the ...